Myonex, a leader in clinical trial supply, has announced the acquisition of Creapharm Group’s clinical and commercial packaging, as well as bioservices divisions. The agreement includes Creapharm’s facilities in Reims, Bordeaux, Bailly-Romainvilliers, and Marietta, Georgia.
Awaiting regulatory approval, this deal is poised to enhance Myonex’s market presence in drug sourcing, clinical trial management, and ancillary services.
The merger is expected to synergize Myonex’s clinical packaging and distribution capabilities with Creapharm’s expertise in the same field, including commercial packaging and supply chain management for advanced therapy medicinal products (ATMPs).
Post-transaction, Myonex will retain Mike Cohen as Executive Chairman and James Lovett as CEO. Eric Placet is set to join the Myonex Board of Directors after reinvesting in the company, while Creapharm’s Carla Da Costa and Edouard Placet will assume strategic roles within the new management structure. The completion of this transaction remains contingent on the satisfaction of regulatory conditions.
“By combining, we will fill a gap in the market with broad and deep expertise, integrated services, and extraordinary client focus,” said James Lovett, CEO of Myonex. “Myonex looks forward to combining with our Creapharm colleagues to meet the needs of our clients with agility and speed.”
“Growing with Myonex is an obvious step for Creapharm to move forward, contributing our expertise and wide range of packaging solutions to their operations while we will expand the range of services we offer in support of always more effective, efficient, patient-centric clinical trials,” said Eric Placet, Creapharm’s CEO and Founder.
“Creapharm is pleased to evolve the overall mission of Myonex through our complementary strengths and to provide scale and flexibility in meeting our clients’ needs.”
“We have complementary strengths and cultural alignment that make this an exciting solution for the industry, our colleagues and clients,” said Michael Cohen, Myonex’s Co-Owner, and Executive Chairman.
“We share traditions of entrepreneurship and engagement with team members, as well as a commitment to social and environmental responsibility to ensure the success of our clients, clinical trial sites and patients.”
